Exploratory Biomarker Analysis of DESTINY-CRC01, a Phase 2, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-DXd, DS-8201) in Patients (pts) With HER2-Expressing Metastatic Colorectal Cancer (mCRC)
Trastuzumab Deruxtecan
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Exploratory Biomarker Analysis of DESTINY-CRC01, a Phase 2, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-DXd, DS-8201) in Patients (pts) With HER2-Expressing Metastatic Colorectal Cancer (mCRC) ### Output: Trastuzumab Deruxtecan